Stay updated with breaking news from Aser Surgery. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Gilead Sciences said even though Trodelvy missed the main goal of its Phase 3 test in non-small cell lung cancer, the drug’s preliminary results show numerical improvement in patients whose disease did not respond to prior treatment with immunotherapy. The company plans to discuss with regulators a possible path forward in these patients.
Turquoise Health closed a $30 million Series B round, which brings its total funding to date to $55 million. The San Diego-based startup, which has more than 160 customers, sells a platform that makes it easier for hospitals and payers to comply with price transparency regulations.
In 2024, the weight loss market finds itself at a crossroads, grappling with pivotal questions that will shape the future. The winners will prioritize affordable lifelong care, scalable coaching and support, and a diverse set of solutions that give people second and third chances along their weight loss journeys.
Sanofi is acquiring Inhibrx to get its hands on a drug candidate in pivotal testing for the protein deficiency alpha-1 antitrypsin deficiency, which leads to lung and liver problems. Inhibrx’s remaining assets will be spun out into a new company.
Adoption of value-based care has been slower in rural communities. With many rural providers struggling to even stay afloat, it can be difficult to switch to value-based care, according to one healthcare executive.